Arvinas ARVN
Arvinas FY 2023: revenue $78.5M, down 40%; diluted EPS −$6.62
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001655759-24-000018
- Document
- 10-K
Key figures from this report
These are the numbers Arvinas reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$78.5M−40% from $131.4M in FY 202210-K income statement, on EDGAR
- Net income−$367.3MAgainst −$282.5M in FY 202210-K income statement, on EDGAR
- Diluted EPS−$6.62Against −$5.31 in FY 202210-K income statement, on EDGAR
- Cash and cash equivalents$311.7M+283% from $81.3M in FY 2022Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$347.8MAgainst −$273.5M in FY 202210-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Arbutus Biopharma ABUS public float $472M, Jun 30, 2025
- aTYR PHARMA ATYR public float $464M, Jun 30, 2025
- Zevra Therapeutics ZVRA public float $455M, Jun 30, 2025
- Theravance Biopharma TBPH public float $449M, Jun 30, 2025
- Myriad Genetics MYGN public float $494M, Jun 30, 2025
